drugset / Trial / NCT01233492

Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme

NCT01233492

Phase 1 Terminated 36 enrolled Cancer Research UK
Open-labelTreatment

Summary

RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as boron neutron capture therapy, for patients in the future. PURPOSE: This phase I trial is studying the side effects, best dose boron phenylalanine, and best way of giving it with or without mannitol in treating patients with glioblastoma multiforme.

Timeline

Start
2007-10
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent Other
Subject boron phenylalanine Unknown Intravenous